Evaluation of commercial antiglobulin sera over a two-year period. Part II. Anti-IgG and anti-IgM levels and undesirable contaminating antibodies.
Antiglobulin sera, from nine different manufacturers, have been tested over a two-year period for their ability to detect different nonagglutinating, IgG and IgM blood group antibodies and for the presence of undesirable antibodies that cause the agglutination of nonglobulin coated red blood cells. There are not so many differences in anti-IgG levels among the sera as there are differences in anticomplement levels. Over the two-year period, there have been, in general, increases in the amounts of anti-IgM antibodies in the sera tested. Several of the sera, apparently prepared by dilution of raw rabbit serum and not by adsorption, contain antibodies that cause the agglutination of red blood cells not coated with IgG, IgM, or any of the components of complement.
Paul I. Hoxworth Blood Center of the University of Cincinnati, Cincinnati, Ohio, 45229, USA.
P D
PD
Issitt
C H
CH
Issitt
S L
SL
Wilkinson
D000373:Agglutinins / Q000097:blood; D000906:Antibodies / Q000097:blood*; D000888:Antibodies, Anti-Idiotypic / Q000097:blood*; D003169:Complement Inactivator Proteins / Q000032:analysis; D003298:Coombs Test; D006801:Humans
D000373:Agglutinins; D000906:Antibodies; D000888:Antibodies, Anti-Idiotypic; D003169:Complement Inactivator Proteins; C048844:anti-IgG; C044203:anti-IgM; C012749:anticomplement